[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Ahn MJ, Park YW, Han D, Choi JH, Shin SJ, Yoon BC, Choi HS, Lee YY, Jung TJ, Choi IY, Park MH, Kim IS: A case of primary intestinal T-cell lymphoma involving entire gastrointestinal tract: esophagus to rectum. Korean J Intern Med; 2000 Dec;15(3):245-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary intestinal T-cell lymphoma involving entire gastrointestinal tract: esophagus to rectum.
  • Primary intestinal T-cell lymphoma is a rare disease entity, which is approximately 10% to 25% of intestinal lymphomas, and most of the lymphomas occur in the small intestine.
  • Gastroscopic examination showed diffuse erythematous lesions on the esophagus and small gastric ulcerations on the antrum of the stomach, and colonoscopic examination also showed multiple punched-out ulcerations and erosions on the entire colon, including the sigmoid colon to the terminal ileum.
  • Diffuse infiltration of CD 3 positive lymphoma cells was found on biopsy.
  • The patient was diagnosed as primary intestinal T-cell lymphoma with diffuse involvement of the entire gastrointestinal tracts from the esophagus to the rectum.
  • Although the patient received systemic combination chemotherapy and achieved partial response initially, the lymphoma relapsed repeatedly.
  • [MeSH-major] Esophageal Neoplasms / therapy. Gastrointestinal Neoplasms / therapy. Lymphoma, T-Cell / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242815.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4531775
  •  go-up   go-down


2. Dalkic E, Wang X, Wright N, Chan C: Cancer-drug associations: a complex system. PLoS One; 2010 Apr 02;5(4):e10031
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-drug associations: a complex system.
  • BACKGROUND: Network analysis has been performed on large-scale medical data, capturing the global topology of drugs, targets, and disease relationships.
  • Analysis of these smaller networks can help address questions, i.e., what governs the pairing of the different cancers and drugs, is it driven by molecular findings or other factors, such as death statistics.
  • We generated two cancer networks, one of cancer types that share Food and Drug Administration (FDA) approved drugs (FDA cancer network), and another of cancer types that share clinical trials of FDA approved drugs (clinical trial cancer network).
  • Breast cancer is the only cancer type with significant weighted degree values in both cancer networks.
  • Lung cancer is significantly connected in the FDA cancer network, whereas ovarian cancer and lymphoma are significantly connected in the clinical trial cancer network.
  • Correlation and linear regression analyses showed that global lethality impacts the drug approval and trial numbers, whereas, local lethality impacts the amount of drug sharing in trials and approvals.
  • However, this effect does not apply to pancreatic, liver, and esophagus cancers as the sharing of drugs for these cancers is very low.
  • We also collected mutation target information to generate cancer type associations which were compared with the cancer type associations derived from the drug target information.
  • The analysis showed a weak overlap between the mutation and drug target based networks.
  • The networks of cancer-drug associations are moderately affected by the death statistics.
  • A strong overlap does not exist between the cancer-drug associations and the molecular information.
  • Overall, this analysis provides a systems level view of cancer drugs and suggests that death statistics (i.e. global vs. local lethality) have a differential impact on the number of approvals, trials and drug sharing.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2003 Nov;13(11):2498-504 [14597658.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Lancet. 1986 Apr 5;1(8484):765-7 [2870269.001]
  • [Cites] Cancer Res. 1992 May 1;52(9 Suppl):2702s-2706s [1314134.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8685-90 [17502601.001]
  • [Cites] BMC Pharmacol. 2008;8:5 [18318892.001]
  • [Cites] N Engl J Med. 2007 Jul 26;357(4):404-7 [17652657.001]
  • [Cites] Natl Vital Stat Rep. 2007 Aug 21;55(19):1-119 [17867520.001]
  • [Cites] Nat Biotechnol. 2007 Oct;25(10):1110-1 [17921993.001]
  • [Cites] Nat Biotechnol. 2007 Oct;25(10):1119-26 [17921997.001]
  • [Cites] Int J Biol Sci. 2008;4(1):15-22 [18167532.001]
  • [Cites] Mt Sinai J Med. 2007 Apr;74(1):27-32 [17516560.001]
  • (PMID = 20368808.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / R21 RR024439; United States / NIEHS NIH HHS / ES / P42 ES004911; United States / NIGMS NIH HHS / GM / R01 GM079688; United States / NCI NIH HHS / CA / R21CA126136-01; United States / NIGMS NIH HHS / GM / R01GM079688-01; United States / NCRR NIH HHS / RR / R21RR024439; United States / NCI NIH HHS / CA / R21 CA126136
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2848862
  •  go-up   go-down


3. Tröger U, Stötzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP: Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ; 2002 Jun 22;324(7352):1497
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Barrett Esophagus / drug therapy. Drug Interactions. Humans. Lymphoma, T-Cell, Cutaneous / drug therapy. Male. Middle Aged. Omeprazole / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Muscle Disorders.
  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. PANTOPRAZOLE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ther Drug Monit. 1991 Nov;13(6):528-32 [1771651.001]
  • [Cites] J Rheumatol. 1994 Jul;21(7):1224-6 [7966062.001]
  • [Cites] Semin Arthritis Rheum. 1998 Apr;27(5):277-92 [9572710.001]
  • [Cites] Rheum Dis Clin North Am. 1997 Nov;23(4):939-54 [9361162.001]
  • [Cites] Acta Derm Venereol. 1995 Sep;75(5):393-6 [8615062.001]
  • (PMID = 12077038.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Benzimidazoles; 0 / Dermatologic Agents; 0 / Sulfoxides; D8TST4O562 / pantoprazole; KG60484QX9 / Omeprazole; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC116448
  •  go-up   go-down


Advertisement
4. Sumi M, Takaku T, Iguchi T, Ishii Y, Katagiri T, Tauchi T, Serizawa H, Mukai K, Ohyashiki K: [Primary diffuse large B-cell lymphoma of the esophagus]. Rinsho Ketsueki; 2004 Sep;45(9):1067-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of the esophagus].
  • A 64-year-old man with primary esophageal lymphoma suffered from dysphagia.
  • An upper gastrointestinal examination revealed a partly ulcerated submucosal tumor in the upper portion of the esophagus.
  • Histopathological and immunohistological examination of endoscopic biopsy specimens showed diffuse large B-cell lymphoma of the immunoblastic type.
  • Improvement of the dysphagia and esophageal findings were noted after chemotherapy and radiotherapy.
  • A review of the literature indicated that primary esophageal lymphomas account for less than 1% of all gastrointestinal lymphomas, and less than 0.1% of all malignant lymphomas.
  • Because of the rarity of primary esophageal lymphoma, its clinical and biological characteristics are not currently well known.
  • It is important to accumulate information on, and to further investigate patients with, primary esophageal lymphoma.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15510839.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Isomoto H, Nishida Y, Fukuda H, Matsuo Y, Omagari K, Mizuta Y, Murase K, Murata I, Kohno S: Two cases of adult T-cell leukaemia/lymphoma with oesophageal involvement. Eur J Gastroenterol Hepatol; 2002 Apr;14(4):449-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of adult T-cell leukaemia/lymphoma with oesophageal involvement.
  • We describe two cases of adult T-cell leukaemia/lymphoma (ATLL) with oesophageal involvement.
  • The first case, a 51-year-old Japanese woman with an acute subtype of ATLL, had an irregular ulcerative lesion in the distal oesophagus.
  • The second case, a 76-year-old Japanese man with a lymphoma subtype of ATLL, had a polypoid lesion in the middle portion of the oesophagus.
  • Combination chemotherapy was ineffective in both cases.
  • Prospective and careful examination of additional cases may eventually provide specific advice for treatment of this unusual condition.
  • [MeSH-major] Esophagus / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11943963.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Tagami K, Tanda S, Tokumura H, Yamaguchi M: [A case of triple malignant tumors consisting of esophagus, stomach and malignant lymphoma with a histopathological feature of collision between gastric cancer and malignant lymphoma--a case report]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2891-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of triple malignant tumors consisting of esophagus, stomach and malignant lymphoma with a histopathological feature of collision between gastric cancer and malignant lymphoma--a case report].
  • We report a rare case of a collision between a gastric cancer and a malignant lymphoma with a wide systemic metastasis, combined with esophagus cancer, stomach cancer and malignant lymphoma.
  • He was diagnosed with malignant diffuse large B cell lymphoma by immunostaining from the extirpated right testis.
  • He received six cycles of R-CHOP therapy.
  • Thereafter, we performed MTX-HOPE therapy as a salvage therapy for four cycles.
  • During this chemotherapy, he felt epigastralgia; esophagus cancer (squamous cell carcinoma) and stomach cancer (highly-differentiated adenocarcinoma) were found by upper endoscopy.
  • However, the gastrointestinal cancer was inoperable, since the malignant lymphoma was progressive.
  • His general status had been exacerbated, and he died about one year after he was diagnosed with malignant lymphoma.
  • Pathological examination revealed that the adenocarcinoma had partly collided with the malignant lymphoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160264.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Koharazawa H, Yamaji S, Takasaki H, Takabayashi M, Fujimaki K, Taguchi J, Kanamori H, Ishigatsubo Y: [Triple secondary malignancy of gingiva, palate and esophagus after an allogeneic bone marrow transplantation for cutaneous T-cell lymphoma]. Rinsho Ketsueki; 2005 Jul;46(7):496-500
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Triple secondary malignancy of gingiva, palate and esophagus after an allogeneic bone marrow transplantation for cutaneous T-cell lymphoma].
  • A 31-year-old man was diagnosed as having cutaneous T-cell lymphoma in January 1994.
  • He received an allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling donor in May 1995, because of refractoriness to chemotherapy.
  • The patient had been treated with immunosuppressants including prednisolone and cyclosporin A for chronic graft-versus-host disease (GVHD) of the extensive type following acute GVHD.
  • Five years after the BMT, he developed moderately differentiated squamous cell carcinoma (SCC) on the mandibular gingival mucosa and underwent surgical resection.
  • Furthermore, 6 years after the BMT well differentiated SCC developed on his palate and was resected.
  • Concurrently, he was diagnosed as having esophageal cancer (poorly differentiated SCC) and underwent a subtotal esophagotomy.
  • One year later he had a recurrence of the esophageal cancer with dysphagia and was treated with radiation and chemotherapy.
  • He remains free of triple cancer and lymphoma.
  • [MeSH-major] Bone Marrow Transplantation. Carcinoma, Squamous Cell. Esophageal Neoplasms. Gingival Neoplasms. Lymphoma, T-Cell, Cutaneous / therapy. Neoplasms, Second Primary. Palatal Neoplasms. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Graft vs Host Disease / complications. Humans. Immunosuppressive Agents / adverse effects. Male. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation / adverse effects


8. Hosoya Y, Yokoyama T, Arai W, Hyodo M, Nishino H, Sugawara Y, Yasuda Y, Nagai H: Tracheoesophageal fistula secondary to chemotherapy for malignant B-cell lymphoma of the thyroid: successful surgical treatment with jejunal interposition and mesenteric patch. Dis Esophagus; 2004;17(3):266-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tracheoesophageal fistula secondary to chemotherapy for malignant B-cell lymphoma of the thyroid: successful surgical treatment with jejunal interposition and mesenteric patch.
  • We report a case of tracheoesophageal fistula (TEF) secondary to chemotherapy for primary thyroid lymphoma.
  • A 65-year-old man with a short history of a rapidly enlarging neck mass was diagnosed as having thyroid lymphoma of diffuse, large B-cell type.
  • The TEF occurred during the first course of chemotherapy including cyclophosphamide, doxorubicin, vincristine and prednisolone.
  • After placing a feeding gastrostomy without oral intake, eight cycles of chemotherapy were completed and complete remission was achieved.
  • Although the cervical mass disappeared, TEF and esophageal stenosis persisted.
  • Total thyroidectomy and resection of the stenotic cervical esophagus were carried out followed by interposition of the revascularized jejunum and its mesenteric patch to cover the TEF.
  • This seems to be the first report of a TEF caused by chemotherapy for primary thyroid B-cell lymphoma.
  • A variety of treatments for TEF including simple closure, tracheal resection, colonic bypass and muscle flap have been reported with low success rates.
  • Our procedure using a jejunal mesenteric patch seems to be unique and may be a new treatment strategy for TEF.

  • Genetic Alliance. consumer health - Tracheoesophageal fistula.
  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361103.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


9. Katsura Y, Suzukawa K, Kojima H, Yoshida C, Shimizu S, Mukai H, Hasegawa Y, Imagawa S, Mori N, Nagasawa T: Cytotoxic T-cell lymphoma arising in Behçet disease. Int J Hematol; 2003 Apr;77(3):282-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic T-cell lymphoma arising in Behçet disease.
  • The case of a 49-year-old man with peripheral T-cell lymphoma arising in Behcet disease (BD) is reported.
  • A left perirenal mass emerged, and a computed tomography-guided needle biopsy of the tumor revealed the infiltration of small- and medium-sized lymphoma cells.
  • A diagnosis of non-Hodgkin's lymphoma (diffuse medium, T-cell) was made.
  • Standard combination chemotherapy diminished the perirenal and orbital lesions.
  • Lymphoma cell infiltration in the esophagus was detected after chemotherapy, and the patient died of massive bleeding from the gastrointestinal tract.
  • Non-Hodgkin's lymphoma is rarely associated with BD, and only 7 cases have been reported in the literature.
  • We have summarized the published case reports of malignant lymphoma arising in BD.
  • To our knowledge, this case report is the first to describe cytotoxic T-cell lymphoma arising in Behçet disease.
  • [MeSH-major] Behcet Syndrome / complications. Lymphoma, T-Cell / etiology. T-Lymphocytes, Cytotoxic / pathology
  • [MeSH-minor] Antigens, CD / analysis. Clone Cells / immunology. Humans. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S46-55 [9894469.001]
  • [Cites] J Gastroenterol. 1997 Apr;32(2):241-5 [9085175.001]
  • [Cites] Ann Rheum Dis. 2001 Nov;60(11):996-1002 [11602462.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):317-26 [10830738.001]
  • [Cites] Arthritis Rheum. 1974 Jul-Aug;17(4):383-90 [4604718.001]
  • [Cites] No To Shinkei. 1992 Nov;44(11):1029-33 [1296716.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):296-301 [10680899.001]
  • [Cites] Int J Tissue React. 1988;10(2):59-65 [3053482.001]
  • [Cites] Ann Dermatol Venereol. 1990;117(11):885-7 [2099715.001]
  • [Cites] N Engl J Med. 1999 Oct 21;341(17):1284-91 [10528040.001]
  • [Cites] Ann Intern Med. 1976 Jan;84(1):68-76 [1106291.001]
  • [Cites] Intern Med. 1993 Aug;32(8):663-7 [8312668.001]
  • [Cites] Clin Rheumatol. 2001;20(4):239-44 [11529628.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):193-207 [10697278.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):313-23 [9578080.001]
  • [Cites] Rinsho Ketsueki. 1992 Feb;33(2):211-5 [1635171.001]
  • [Cites] Ann Rheum Dis. 1986 Sep;45(9):789 [3767471.001]
  • [Cites] Acta Pathol Jpn. 1974 Jan;24(1):141-50 [4406401.001]
  • [Cites] Arthritis Rheum. 1982 Nov;25(11):1343-51 [6215926.001]
  • [Cites] Arthritis Rheum. 1982 Sep;25(9):1130-3 [7126297.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1998 Oct;236(10):798-9 [9801898.001]
  • [Cites] Rinsho Ketsueki. 1997 Aug;38(8):657-62 [9311271.001]
  • [Cites] Nephron. 1999 Feb;81(2):239 [9933762.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1728-33 [8826934.001]
  • (PMID = 12731673.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunosuppressive Agents
  • [Number-of-references] 25
  •  go-up   go-down


10. Perego D, Casella G, Bonavina L, Pozzetti U, Soligo D, Incarbone R, Buda CA, Baldini V: Esophageal involvement as an uncommon modality of relapse of Hodgkin lymphoma. Dis Esophagus; 2003;16(3):270-2
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal involvement as an uncommon modality of relapse of Hodgkin lymphoma.
  • We present a case of systemic Hodgkin's lymphoma, relapsed with esophageal involvement after 3 years of complete remission.
  • Esophagectomy and chemotherapy followed by bone marrow transplantation allowed a complete response and the long-term survival of the patient.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14641325.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Buła G, Bichalski WR, Waler JM, Podwińska E: [Malignant thyroid lymphoma--diagnostic and treatment problems]. Wiad Lek; 2002;55(3-4):144-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant thyroid lymphoma--diagnostic and treatment problems].
  • The aim of this study was to present our experience in the diagnostics and treatment of primary malignant thyroid lymphoma (PMTL).
  • They made up 0.04% of patients operated on at this time in our Department because of different types of goiter and 1.05% because of thyroid carcinoma.
  • Surgical treatment--partial excision of neoplastic tumor--was complicated by tracheostomy in two cases.
  • One case with almost total resection of thyroid gland was complicated by lesion of esophagus which was sutured.
  • After operation one patient was treated with chemotherapy, one with radiotherapy and two cases using both of methods.
  • One of them was treated with Co 60 therapy and the second one with chemotherapy according to COP and radiotherapy.
  • The treatment of PMTL combined, including surgical treatment, chemo- and radiotherapy.
  • [MeSH-major] Lymphoma / diagnosis. Lymphoma / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Aged. Biopsy, Needle. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Poland. Remission Induction. Retrospective Studies

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12181998.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


12. Uemura Y, Imai T, Nakajim T, Urata T, Doi H: [A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol]. Nihon Kokyuki Gakkai Zasshi; 2010 Jan;48(1):28-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol].
  • A 56-year-old man had an endoscopic examination for dysphagia in March 2007 which revealed tumors in the esophagus and stomach.
  • Pathological examination of the esophagus biopsy specimens showed an unspecified peripheral T cell lymphoma.
  • The esophagus tumor was tolerant to CHOP and EPOCH therapy.
  • However, a lymphoma relapse was diagnosed in the lung in September 2008.
  • The relapsed lung lymphoma was tolerant to EPOCH therapy.
  • The refractory pulmonary peripheral T cell lymphoma was remarkably reduced by PEGS therapy.
  • PEGS therapy is useful for relapsed peripheral T cell lymphoma cases that tolerated standard chemotherapy.
  • An allogenic hematopoietic stem cell transplantation or new molecular target therapy might be finally selected for refractory peripheral T cell lymphoma.
  • Furthermore we could not easily try phase I or II new molecular target drug treatment.
  • We think that PEGS therapy is a useful treatment for refractory peripheral T cell lymphoma before allogenic transplantation or new molecular target drug treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lymphoma, T-Cell, Peripheral / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163018.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0W860991D6 / Deoxycytidine; 5GMR90S4KN / Methylprednisolone Hemisuccinate; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Re A, Cattaneo C, Michieli M, Casari S, Spina M, Ferremi P, Mazzuccato M, Carosi G, Tirelli U, Rossi G: High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma.
  • : 6506 Background: The introduction of highly active antiretroviral therapy (HAART), has allowed the evaluation of aggressive therapeutic approaches in HIV-associated lymphoma (HIV-Ly).
  • METHODS: We report the results of a multiinstitutional program of high dose therapy (HDT) and autologous peripheral blood stem cell (PBSC) transplantation in HAART responsive pts with HIV-Ly refractory or relapsed after standard dose chemotherapy (CT).
  • Pts with active opportunistic infections (OI) or CNS lymphoma were excluded.
  • Two had early disease progression; one is on treatment and 14 received the BEAM regimen and PBSC transplantation with prompt engraftment in all (neutrophils and plt engraftment: 10 (8-10) and 12 days (8-18)).
  • Treatment-related toxicities (WHO grade 3-4): 3 oral mucositis (3) and 2 hepatic toxicity (3).
  • OI: 2 varicella zooster at 3 and 5 mo and 2 esophagus candidosis at 1 and 9 mo.
  • CD4 count decreased after treatment, but a trend toward recovery is seen few mo after transplant.
  • CONCLUSIONS: Our data confirm on a multiinstitutional basis that HDT and PBSC transplantation is feasible and active as salvage therapy in HIV-Ly in unselected HAART responding patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kim JH, Lee JH, Lee J, Oh SO, Chang DK, Rhee PL, Kim JJ, Rhee JC, Lee J, Kim WS, Ko YH: Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings. Endoscopy; 2007 Feb;39(2):156-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings.
  • BACKGROUND AND STUDY AIMS: Primary NK-/T-cell lymphoma of the gastrointestinal tract is a very rare disease with a poor prognosis.
  • The aim of this study was to determine the clinical and endoscopic characteristics of patients with primary gastrointestinal NK-/T-cell lymphoma.
  • PATIENTS AND METHODS: The clinical features of 14 patients with primary gastrointestinal NK-/T-cell lymphoma and the endoscopic findings in 11 of these patients were reviewed.
  • Their median age was 42 years (range 23-78) at the time of diagnosis.
  • RESULTS: The initial presenting symptoms of primary gastrointestinal NK-/T-cell lymphoma were gastrointestinal bleeding (n = 6, 42%), abdominal pain (n = 4, 29%), and epigastric soreness (n = 4, 29%).
  • The disease was at an advanced stage at the time of diagnosis: stage II in 5 patients (36%); stage III in 4 (28%); and stage IV in 5 (36%).
  • Initial treatment was with chemotherapy (n = 8, 57%) or surgical resection (n = 5, 36%).
  • On endoscopy in 11 patients, the anatomic location of the primary lesion was found to be: stomach, n = 3 (27%); esophagus, n = 2 (18%); duodenum, n = 1 (9%); and the ileocolonic area, n = 5 (46%).
  • CONCLUSIONS: Primary gastrointestinal NK-/T-cell lymphoma was endoscopically characterized by superficial/erosive, ulcerative, or ulceroinfiltrative lesions without fungating mass.
  • Despite aggressive treatments, the prognosis was very poor.
  • [MeSH-major] Endoscopy, Gastrointestinal. Gastrointestinal Neoplasms / pathology. Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657701.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • All patients were staged by computed tomography scanning and bone marrow examination, in addition to the endoscopic evaluation.
  • RESULTS: All patients were males; 4 were heterosexual, 2 homosexual, and 1 were a hemophilic and an intravenous drug abuser.
  • The median age was 42 years and the median CD4 T cell count was 87 cells/uL at the time of the diagnosis of neoplasm.
  • No patient was receiving highly active antiretroviral therapy (HAART) at lymphoma diagnosis.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • All patients presented "B" symptoms at the time of diagnosis.
  • Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.
  • Four patients were treated with systemic chemotherapy with granulocitic growth factor support plus highly active antiretroviral therapy (HAART); 2 of them (cavum and one of the colon) had a prolonged survival with immune reconstitution during 5 and 6 years, respectively, after the diagnosis.
  • The median survival of the patients, which received HAART plus chemotherapy, was 33 months.
  • Early diagnosis followed by chemotherapy plus HAART are necessary to improve the prognosis and the survival of these patients.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225446.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


16. Remes-Troche JM, De-Anda J, Ochoa V, Barreto-Zuñiga R, Arista-Nasr J, Valdovinos MA: A rare case of multiple lymphomatous polyposis with widespread involvement of the gastrointestinal tract. Arch Pathol Lab Med; 2003 Aug;127(8):1028-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple lymphomatous polyposis (MLP) is an uncommon type of primary non-Hodgkin gastrointestinal (GI) B-cell lymphoma characterized by the presence of multiple polyps along the GI tract.
  • Malignant cells of MLP have mantle cell characteristics and thus are considered to be the counterpart of the mantle cell lymphoma (MCL) in the GI tract.
  • The lymphomatous polyps extended from the esophagus to the rectum, with bone marrow infiltration.
  • The patient was treated with a combined cyclophosphamide, vincristine, and prednisone chemotherapy regimen, resulting in a partial response.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Intestinal Polyps / pathology. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / pathology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12873180.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Beutner EH, Pelton S, Hashimoto T, Xu Y, Plunkett RW, Korman NJ, Helm TN, Jablonska S: A nonfatal case and 2 fatal cases of paraneoplastic pemphigus: can a complement indirect immunofluorescent test help to identify fatal "group A" paraneoplastic pemphigus cases? J Am Acad Dermatol; 2002 Dec;47(6):841-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient received no treatment after the appearance of PNP and recovered completely from both PNP and lymphoma.
  • Multiple serum studies of these 3 patients plus 9 other proven PNP cases revealed that 8 of 9 fatal PNP cases (referred to here as "group A") had distinctive cell surface antibodies detected by complement indirect immunofluorescent (CIIF) tests on monkey esophagus sections.
  • [MeSH-minor] Biopsy, Needle. Fatal Outcome. Follow-Up Studies. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Risk Assessment. Sarcoma / diagnosis. Sarcoma / radiotherapy. Sensitivity and Specificity. Severity of Illness Index. Skin Neoplasms / diagnosis. Skin Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12451367.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR0016
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear
  •  go-up   go-down


18. Várady E, Deák B, Molnár ZS, Rosta A, Schneider T, Esik O, Eckhardt S: Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma; 2001 Nov-Dec;42(6):1275-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment for Hodgkin's disease.
  • The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem.
  • Second neoplasm developed in 32 cases (4.8%).
  • Five patients received chemo- and radiotherapy and in two cases chemotherapy was used.
  • Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed.
  • Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy.
  • Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911408.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Herget GW, Riede UN, Schmitt-Gräff A, Lübbert M, Neumann-Haefelin D, Köhler G: Generalized herpes simplex virus infection in an immunocompromised patient--report of a case and review of the literature. Pathol Res Pract; 2005;201(2):123-9
MedlinePlus Health Information. consumer health - Herpes Simplex.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with immunodeficiency or treatment-related immunosuppression are at an increased risk of developing severe herpes simplex virus (HSV) infection.
  • Autopsy revealed non-perioral herpetic skin lesions and mucosal ulceration of the esophagus and colon.
  • Numerous petechiae were observed on the mucosal surface of the esophagus, jejunum, ileum, and colon.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Female. Humans. Immunohistochemistry. Polymerase Chain Reaction. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Simplexvirus / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901133.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Ikegaya S, Yoshida A, Iwasaki H, Naiki H, Ueda T: Esophageal erosion as a possible bacterial entry site in an acute lymphoblastic leukemia patient with sepsis. Int J Hematol; 2003 May;77(4):395-8
MedlinePlus Health Information. consumer health - Sepsis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal erosion as a possible bacterial entry site in an acute lymphoblastic leukemia patient with sepsis.
  • During this chemotherapy, the patient developed sepsis and meningitis.
  • Although many kinds of antimicrobial drugs, including imipenem, meropenem, amphotericin-B, and gamma-globulin were administered, the patient died of respiratory failure.
  • Autopsy revealed multiple small erosions in the lower esophagus.
  • [MeSH-major] Esophageal Diseases / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Sepsis / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autopsy. Enterococcus faecalis. Fatal Outcome. Gram-Positive Bacterial Infections / etiology. Humans. Male. Meningitis / etiology. Meningitis / microbiology. Middle Aged. Neutropenia / chemically induced. Neutropenia / microbiology. Respiratory Insufficiency

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1997 Sep;25(3):551-73 [9314442.001]
  • [Cites] Am J Hematol. 1983 Aug;15(1):57-63 [6349334.001]
  • [Cites] Kansenshogaku Zasshi. 1990 Mar;64(3):299-309 [2193067.001]
  • [Cites] Int J Hematol. 2000 Apr;71(3):266-72 [10846834.001]
  • [Cites] Kansenshogaku Zasshi. 1996 Feb;70(2):108-15 [8851382.001]
  • [Cites] Z Gastroenterol. 1996 May;34(5):286-95 [8686361.001]
  • [Cites] Cancer. 1977 Mar;39(3):1345-9 [912664.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1233-9 [7543176.001]
  • (PMID = 12774931.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Lee TC, Dreyer ZE, Brandt ML: Conservative surgical treatment of a profoundly immunosuppressed pediatric patient with Boerhaave syndrome. J Pediatr Hematol Oncol; 2005 Nov;27(11):616-7
MedlinePlus Health Information. consumer health - Esophagus Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative surgical treatment of a profoundly immunosuppressed pediatric patient with Boerhaave syndrome.
  • Boerhaave syndrome is a condition described as spontaneous rupture of the esophagus that often results in mediastinitis, sepsis, and death.
  • At the time of diagnosis (10 days after rupture), the patient had an absolute neutrophil count of 0 and was treated with T-tube drainage of the perforation.
  • The patient has required three endoscopic esophageal dilatations of a mild esophageal stricture.
  • [MeSH-major] Esophageal Diseases / surgery
  • [MeSH-minor] Humans. Immunocompromised Host. Infant. Leukocyte Count. Male. Neutrophils / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction. Rupture, Spontaneous. Syndrome

  • Genetic Alliance. consumer health - Boerhaave Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282895.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R, van der Graaf WT, Coebergh JW, van Leeuwen FE: Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol; 2008 Mar 10;26(8):1239-46
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.
  • PURPOSE: To assess the risk of secondary nonbreast cancers (SNBCs) in a recently treated population-based cohort of breast cancer patients focused on the association with treatment and prognostic implications.
  • SIRs were elevated for cancers of the esophagus, stomach, colon, rectum, lung, uterus, ovary, kidney, and bladder cancers, and for soft tissue sarcomas (STS), melanoma, non-Hodgkin's lymphoma, and acute myeloid leukemia (AML).
  • Among patients younger than 50 years, radiotherapy was associated with an increased lung cancer risk (hazard ratio [HR] = 2.31; 95% CI, 1.15 to 4.60) and chemotherapy with decreased risk for all SNBCs (HR = 0.78; 95% CI, 0.63 to 0.98) and for colon and lung cancer.
  • Among patients age 50 years and older, radiotherapy was associated with raised STS risk (HR = 3.43; 95% CI, 1.46 to 8.04); chemotherapy with increased risks of melanoma, uterine cancer, and AML; and hormonal therapy with all SNBCs combined (HR = 1.10; 95% CI, 1.01 to 1.21) and uterine cancer (HR = 1.78; 95% CI, 1.40 to 2.27).
  • [MeSH-major] Breast Neoplasms / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Middle Aged. Netherlands / epidemiology. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323547.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


23. Lee JS, Pei-Lin Ng P, Tao M, Lim WT: Paraneoplastic pemphigus resembling linear IgA bullous dermatosis. Int J Dermatol; 2006 Sep;45(9):1093-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He had stage IIIA follicular small cell cleaved non-Hodgkin's lymphoma diagnosed 5 years previously, and had received several lines of palliative chemotherapy, including two courses of chlorambucil, six cycles of cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP), and two four-cycle courses of rituximab, with disease stabilization at the time of presentation.
  • Indirect immunofluorescence on monkey esophagus was positive for anti-intercellular antibody at a titre of 1/160 and positive on rat bladder at a titre of 1/80.
  • He declined rituximab therapy.

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961519.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin A
  •  go-up   go-down


24. Amini M, Karbasi A, Khedmat H, Jeihounian M: Helicobacter pylori eradication and histopathological esophagitis in dyspeptic patients. Trop Gastroenterol; 2010 Jul-Sep;31(3):175-9
Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of Helicobacterpylori with peptic ulcer disease, atrophic gastritis, gastric adenocarcinoma, MALT (mucosa associated lymphoid tissue) lymphoma is well recognized.
  • METHODS: Eligible dyspeptic patients referred to Gastroenterology clinic in Baqiyatollah hospital were endoscopied and evaluated for endoscopic and pathologic esophagitis and the H. pylori infection status was determined by rapid urease test. H. pylori infection was treated by an anti H. pylori drug regimen and successfully eradicated patients according to negative C14 urea breath test were followed and re-endoscopy was performed 6-9 months after the end of treatment.
  • [MeSH-major] Esophagitis, Peptic / etiology. Esophagitis, Peptic / pathology. Gastroesophageal Reflux / etiology. Gastroesophageal Reflux / pathology. Helicobacter Infections / drug therapy. Helicobacter pylori
  • [MeSH-minor] Adult. Amoxicillin / administration & dosage. Antacids / administration & dosage. Anti-Bacterial Agents / administration & dosage. Anti-Ulcer Agents / administration & dosage. Bismuth / administration & dosage. Disease Progression. Drug Therapy, Combination. Dyspepsia / drug therapy. Esophagoscopy. Esophagus / pathology. Female. Humans. Iran. Male. Metronidazole / administration & dosage. Middle Aged. Mucous Membrane / pathology. Omeprazole / administration & dosage

  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21560521.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antacids; 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 140QMO216E / Metronidazole; 804826J2HU / Amoxicillin; KG60484QX9 / Omeprazole; U015TT5I8H / Bismuth
  •  go-up   go-down


25. Kobayashi O, Murakami H, Yoshida T, Cho H, Yoshikawa T, Tsuburaya A, Sairenji M, Motohashi H, Sugiyama Y, Kameda Y: Clinical diagnosis of metastatic gastric tumors: clinicopathologic findings and prognosis of nine patients in a single cancer center. World J Surg; 2004 Jun;28(6):548-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The MGTs were diagnosed based on findings in the surgical or endoscopic specimen, and patients with malignant lymphoma or direct invasion from adjacent organs were excluded from the study.
  • MGTs were detected simultaneously with the primary tumors in three and afterward in six patients at 14 to 74 months.
  • The primary tumors included one each of squamous cell carcinoma of the esophagus, signet-ring cell carcinoma of the breast, large-cell or small-cell carcinoma of the lung, renal cell carcinoma, hepatocellular carcinoma, squamous cell or epidermoid carcinoma of the uterus, and melanoma.
  • Five patients were treated by chemotherapy with no apparent survival benefit.
  • A median survival after MGT diagnosis was 170 days (range 16-892 days) for all cases, 384 days for those who underwent gastrectomy (n = 6), and 27 days for those without active treatment (n = 3) (p = 0.002).

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1994 Oct;55(1):152-5 [7959258.001]
  • [Cites] Int J Clin Pract. 2002 Oct;56(8):623-5 [12425377.001]
  • [Cites] Hepatogastroenterology. 2000 Nov-Dec;47(36):1581-4 [11149006.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):25-30 [11957041.001]
  • [Cites] JAMA. 1974 Aug 12;229(7):825-6 [4407823.001]
  • [Cites] Am J Surg. 1991 Sep;162(3):208-11 [1718180.001]
  • [Cites] Indian J Gastroenterol. 1992 Apr;11(2):88 [1428039.001]
  • [Cites] Radiology. 1972 Oct;105(1):1-11 [5066554.001]
  • [Cites] Dig Dis Sci. 1990 Nov;35(11):1421-5 [2226104.001]
  • [Cites] Mayo Clin Proc. 1980 Dec;55(12):747-53 [6261047.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2214-21 [11147591.001]
  • [Cites] Cancer. 1988 May 15;61(10):2134-5 [3359409.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Mar;123(3):512-21 [1124830.001]
  • [Cites] J Gastroenterol. 1994 Feb;29(1):71-5 [7515309.001]
  • [Cites] Gastrointest Endosc. 2000 Aug;52(2):273-5 [10922110.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2235-41 [4052968.001]
  • [Cites] J Clin Gastroenterol. 1981;3 Suppl 1:35-7 [7328295.001]
  • [Cites] Can J Surg. 1962 Oct;5:438-41 [13954414.001]
  • [Cites] Acta Oncol. 1993;32(4):459-60 [8396398.001]
  • [Cites] Acta Chir Belg. 2000 Sep-Oct;100(5):228-30 [11143327.001]
  • [Cites] Thorac Cardiovasc Surg. 1993 Oct;41(5):318-20 [8303703.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10 ):903-13 [1190198.001]
  • [Cites] J Clin Gastroenterol. 1998 Mar;26(2):153-4 [9563931.001]
  • [Cites] Am J Surg. 1960 Jan;99:94-6 [13814449.001]
  • [Cites] Endoscopy. 1996 Feb;28(2):262 [8739747.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):170-2 [6274500.001]
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):566-7 [12297779.001]
  • [Cites] J Gastroenterol. 1994 Aug;29(4):495-500 [7951861.001]
  • [Cites] Am J Gastroenterol. 1985 Jan;80(1):67-9 [3966457.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):363-5 [11474262.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1209-12 [12168927.001]
  • [Cites] Endoscopy. 1998 Nov;30(9):800-4 [9932762.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):507-10 [11437044.001]
  • (PMID = 15366743.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Taub AF: Photodynamic therapy: other uses. Dermatol Clin; 2007 Jan;25(1):101-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy: other uses.
  • Mainstream uses for photodynamic therapy (PDT) in dermatology include nonmelanoma skin cancer and its precursors, acne vulgaris, photorejuvenation, and hidradenitis suppurativa.
  • Many other dermatologic entities have been treated with PDT, including psoriasis, lichen planus, lichen sclerosus, scleroderma, cutaneous T cell lymphoma, alopecia areata, verruca vulgaris, Darier's disease and tinea infections.
  • Nondermatologic applications include anal and vulva carcinoma, palliation of metastatic breast cancer to skin, Barrett's esophagus, and macular degeneration of the retina.
  • The ability of this treatment to hone in on dysplastic epithelial and endothelial cells while retaining viability of surrounding tissue is its key feature because this leads to specific tumor destruction with cosmesis and function of the target organ intact.
  • [MeSH-major] Infection / drug therapy. Neoplasms / drug therapy. Photochemotherapy. Skin Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126748.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


27. Park S, Jeen YT, Kwon YD, Keum B, Seo YS, Kim YS, Chun HJ, Um SH, Kim CD, Ryu HS: Successfully cured primary esophageal lymphoma in a patient with acquired immune deficiency syndrome (AIDS). Endoscopy; 2009;41 Suppl 2:E148-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successfully cured primary esophageal lymphoma in a patient with acquired immune deficiency syndrome (AIDS).
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Esophagoscopy. Humans. Male

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544273.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement